Skip to main content

Trinity College Dublin, The University of Dublin

Trinity Menu Trinity Search



You are here Staff

Dr. Laure Marignol
Associate Professor, Radiation Therapy

Biography

Laure Marignol, PhD is an Associate Professor in Radiobiology at the Discipline of Radiation Therapy in the School of Medicine. She is an Elected Fellow of the University. Head of Research for her Discipline, she drove the creation of the Applied Radiation Therapy Trinity (ARTT) research group, while leading her Translational Radiobiology and Molecular Oncology research laboratory. Dr. Marignol has worked for over 12 years on the problem of the selective destruction of cancer cells with ionising radiation, through the design in vitro models, the molecular classification of disease, and innovations in therapeutic approaches. Her work mostly focused on prostate cancer owing to her close relationship with the Urology Department at St James's Hospital. With close to 100 peer-reviewed research works, she is best known for her earlier work on understanding the molecular impact of oxygenation levels on the response of prostate tumours to radiation. Her research also focuses on novel approaches to improving cell lethality by radiation. She is serving as Chair of the Irish Radiation Research Society and advisor to the Environmental Protection Agency (EPA). She sits on the Radiobiology committee of the European Society for Radiotherapy and Oncology (ESTRO) and joined the Faculty of their course in Basic Clinical Radiobiology. She holds an editorial position with Nature Scientific Reports. Recipient of the highly competitive St Luke's Young Investigator Award of the Royal Irish Academy of Medicine, she was awarded grant funding from the Irish Cancer Society and Science Foundation Ireland. Dr. Marignol is also known for her ability to train students and Health Care Professionals on the research process. She received a Teaching Award from the Dean of the Faculty of Health Sciences to develop her 5-step research guide into the online Trinity Research Education Environment (TREE). Priding herself in being fair, a value most appreciated by her students and peers, Dr. Marignol has developed her career through the combination of a love of learning, a need to be challenged and an awareness that kindness is key to progress. She believes in embracing the possibility of a second chance and takes pleasure in exploring a hunch, in hearing the perspective of others and in encouraging the scientific community to continue to explore her field. She lives near Dublin with her husband and three young children. She regularly visits her family in Avignon, France.

Publications and Further Research Outputs

Peer-Reviewed Publications

Sarah Barrett , Andrew J Simpkin , Gerard M Walls , Michelle Leech , Laure Marignol , Geometric and dosimetric evaluation of a commercially available auto-segmentation tool for gross tumour volume delineation in locally advanced Non-Small Cell Lung Cancer: a feasibility study, Journal of Clinical Oncology, 2020 Journal Article, 2020

James Clerkin, Kate Connor, Kieron Sweeney, Kieron White, Stephen G. Maher, Laure Marignol, Jochen Prehn , David O'Brien, Annette T. Byrne, Establishing a clinically relevant model of Glioblastoma in young and aged mice, encompassing standard of care treatment and immune checkpoint inhibition (ICI, Irish Association for Cancer Research , Galway, February 2020, 2020 Poster, 2020

Wei Ang, Laure Marignol, Pro-con of proton: dosimetric advantages of intensity-modulation over passive scatter for thoracic malignancies , Technical Innovations & Patient Support in Radiation Oncology, 2020 Review Article, 2020

Meunier A, Marignol L., The radiotherapy cancer patient: female inclusive, but male dominated., International journal of radiation biology, 2020, p1-6 Journal Article, 2020 DOI

Darragh Waters , Adrian Fuentes-Bonachera , Armelle Meunier , Rustom P. Manecksha, Laure Marignol and Thomas H. Lynch, Kidney Cancer Research: Sex-Inclusive but Sex-Unspecific, Clinical Oncology and Research, 2020 Journal Article, 2020 URL

Laure Marignol, Radiobiology of particles therapy: principles and latest advances, ESTRO meets Asia , Singapore, 2019, European Society for Radiotherapy and Oncology Invited Talk, 2019 URL

Barrett S, Thirion P, Harper D, Simpkin A, Leech M, Hickey K, Ryan L, Marignol L, Dosimetric impact of uncorrected systematic yaw rotation in VMAT for peripheral lung SABR, . Reports of Practical Oncology & Radiotherapy, 24, (6), 2019, p520 - 527 Journal Article, 2019 URL

Laure Marignol, Molecular radiation response of breast cancer: advances and clinical potential, ESTRO meets Asia , Singapore, 6-8th December, 2019, European Society for Radiotherapy and Oncology Invited Talk, 2019 URL

S Inder, M Bates, N Ni Labhrai, N McDermott, J Schneider, G Erdmann, T Jamerson, AN Flores, A Prina-Mello, P Thirion, PR Manecksha, D Cormican, S Finn, T Lynch, L Marignol, Multiplex profiling identifies clinically relevant signalling proteins in an isogenic prostate cancer model of radioresistance, Scientific Reports, 9, 2019, p1 - 12 Journal Article, 2019 TARA - Full Text DOI

Elbeltagi M.N., Wall V., Marignol L., Planning target volume (PTV) margin practice patterns in adults and paediatrics among the Paediatric Radiation Oncology Society (PROS) members: An international survey, Journal of Radiotherapy in Practice, 17, (4), 2018, p373 - 376, p373-376 Journal Article, 2018 DOI

Wall V, Marignol L, ElBeltagi N., Image-Guided Radiotherapy in Paediatrics: A Survey of International Patterns of Practice., Journal of medical imaging and radiation sciences, 49, (3), 2018, p265-269 Journal Article, 2018 DOI

Glynn A, Marignol L, Forde E, Focal therapy: A treatment option for localized prostate cancer? , Advances in Modern Oncology Research, 2018 Review Article, 2018 DOI

Griffin F., Marignol L., Therapeutic potential of melatonin for breast cancer radiation therapy patients, International Journal of Radiation Biology, 94, (5), 2018, p472 - 477 Review Article, 2018 DOI

Sarah Caufield, Laure Marignol, Gerard Menezes, Claire Poole, Nomograms are key decision making tools in prostate cancer radiation therapy, Urologic Oncology: Seminars and Original Investigations, 36, (6), 2018, p283 - 292 Review Article, 2018

Sarah Barrett, Gerard G. Hanna, Laure Marignol, An overview on personalisation of radiotherapy prescriptions in locally advanced non-small cell lung cancer: Are we there yet?, Radiotherapy and Oncology, 128, (3), 2018, p520 - 533 Review Article, 2018 DOI

Inder, S, Bates, M, McDermott, N, Saluzzo, J, Ni Labhrai, N , Schneider, J, Erdmann, G, Lynch, , Marignol, L, Lessons from isogenic models of radioresistant prostate cancer cells, 37th Meeting of the European-Society-for-Radiotherapy-and-Oncology (ESTRO), Barcelona, SPAIN, 2018 Oral Presentation, 2018 DOI

Marignol L., Predicting Treatment Outcomes: The Case for Hypoxia Gene Signatures., EBioMedicine, 2018 Review Article, 2018 DOI

Samsuri, N.A.B. and Leech, M. and Marignol, L., Metformin and improved treatment outcomes in radiation therapy â€" A review, Cancer Treatment Reviews, 55, 2017, p150-162 Review Article, 2017 DOI

McDermott N, Inder S, Schneider J, Erdmann G,Meunier A., Lynch T, Marignol L, Radioresistance profiling identifies Notch-3 signalling as a molecular switch to molecular radiation response of prostate cancer cells , 15th International Wolfsberg Meeting, Switzerland, 2017 Poster, 2017

Inder, S., O'Rourke, S., McDermott, N., (...), Lynch, T., Marignol, L. , The Notch-3 receptor: A molecular switch to tumorigenesis?, Cancer treatment reviews, 60, 2017, p69-76 Review Article, 2017 DOI

Laure Marignol, Gene editing: How this technique can be used to study radiation responses?, 2017, S1 - S1pp Invited Talk, 2017 DOI

Hutchinson, J., Marignol, L. , Clinical Potential of Statins in Prostate Cancer Radiation Therapy., Anticancer research, 37, (10), 2017, p5363-5372 Review Article, 2017 DOI

Haruna, F., Lipsett, A., Marignol, L. , Topical Management of Acute Radiation Dermatitis in Breast Cancer Patients: A Systematic Review and Meta-Analysis., Anticancer research, 37, (10), 2017, p5343-5353 Journal Article, 2017 DOI

O'Brien, R. and Marignol, L., The Notch-1 receptor in prostate tumorigenesis, Cancer Treatment Reviews, 56, 2017, p36-46 Review Article, 2017 DOI

Inder, S. and Bates, M. and McDermott, N. and Domad, J. and Schneider, J. and Erdmann, G. and Finn, S. and Manecksha, R. P. and Lynch, T. H. and Marignol, L., Identification of a protein signature of radioresistance in a prostate cancer model, The British Association for Urological Surgeons, 120, 2017, pp24-24 Poster, 2017

McDermott N,Inder S, Schneider J, Erdmann G, Meunier A., Lynch T, Marignol L, Identifying a novel molecular switch of the radiation response of prostate cancer cells, Radiation Research Society Annual Meeting, Cancun, Mexico, October 15-18, 2017 Oral Presentation, 2017 URL

McDermott N., Meunier A., Wong S., Buchete V., Marignol L., Profiling of a panel of radioresistant prostate cancer cells identifies deregulation of key miRNAs, Clinical and Translational Radiation Oncology, 2, 2017, p63 - 68 Journal Article, 2017 DOI

Fitzpatrick C, Lynch O, Marignol L., 68Ga-PSMA-PET/CT Has a Role in Detecting Prostate Cancer Lesions in Patients with Recurrent Disease., Anticancer research, 37, (6), 2017, p2753-2760 Review Article, 2017 DOI

Marignol, L., Notch signalling: The true driver of small cell lung cancer?, Translational Cancer Research, 6, 2017, pS1191-S1196 Review Article, 2017 DOI

Michelle Leech, John Gaffney, Laure Marignol, Improving non-invasive detection of prostate cancer using diffusion-weighted MRI, Advances in Modern Oncology Research , 2, (6), 2016 Review Article, 2016

Wall, V. and Marignol, L. and Elbeltagi, M. N., Radiotherapy in Paediatrics: A Survey of International Patterns of Practice of Image Guided Radiation Therapy and Planning Target Volume, 63, 2016, ppS64-S64 Oral Presentation, 2016

Devine A, Marignol L, Potential of Amifostine for Chemoradiotherapy and Radiotherapy-associated Toxicity Reduction in Advanced NSCLC: A Meta-Analysis., Anticancer research, 36, (1), 2016, p5-12 Journal Article, 2016

McDermott N., Meunier A., Mooney B., Nortey G., Hernandez C., Hurley S., Hurley S., Lynam-Lennon N., Barsoom S., Bowman K., Marples B., Jones G., Marignol L., Fractionated radiation exposure amplifies the radioresistant nature of prostate cancer cells, Scientific Reports, 6, 2016 Journal Article, 2016 DOI

McDermott, N.; Meunier, A.; Haynes, C.; Flores, A.; O'Callaghan, A.; Marignol, L., Therapeutic potential of the YB-1/Notch-3 interaction in prostate cancer, 35th Scientific Meeting of the European Society for Radiotherapy and Oncology (ESTRO), Turin, Italy, 2016 Poster, 2016 DOI

Lynam-Lennon N., Bibby B., Mongan A., Marignol L., Paxton C., Geiersbach K., Geiersbach K., Bronner M., Bronner M., O"Sullivan J., Reynolds J., Maher S., Maher S., Low MiR-187 expression promotes resistance to chemoradiation therapy in vitro and correlates with treatment failure in patients with esophageal adenocarcinoma, Molecular Medicine, 22, 2016, p388-397 Journal Article, 2016 DOI

Meunier A., Flores A., McDermott N., Rivera-Figueroa K., Perry A., Lynch T., Redalen K., Marignol L., Hypoxia regulates Notch-3 mRNA and receptor activation in prostate cancer cells, Heliyon, 2, (5), 2016 Journal Article, 2016 DOI

Moran DC, Marignol L, Fagan AJ, Dunne R, Perry AS, O'Driscoll D, Gaffney E, Lynch TH, Meaney JFM, Hollywood DH, Threshold-based parametric analysis of diffusion-weighted magnetic resonance imaging at 3.0 Tesla to identify men with prostate cancer, Adv Mod Oncol Res , 1, (2), 2015, p141 - 150 Journal Article, 2015

McDermott, N. and Meunier, A. and Hernandez, C. and Bowman, K. J. and Jones, G. D. and Marignol, L., Identification of a miRNAs signature of radioresistance in a prostate cancer model, 75, 2015 Poster, 2015 DOI

Lim D, Quah DS, Leech M, Marignol L, Clinical potential of boron neutron capture therapy for locally recurrent inoperable previously irradiated head and neck cancer., Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine, 2015 Journal Article, 2015 DOI TARA - Full Text

Lawlor H, Meunier A, McDermott N, Lynch TH, Marignol L, Identification of suitable endogenous controls for gene and miRNA expression studies in irradiated prostate cancer cells., Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 36, (8), 2015, p6019-28 Journal Article, 2015 DOI

Dullea A, Marignol L, MGMT testing allows for personalised therapy in the temozolomide era., Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2015 Review Article, 2015 DOI

Marignol, L., Targeting notch in prostate cancer - Combination is the key, 11, (7), 2014 Review Article, 2014

Scientific Report, Nature, [eds.], 2014 Editorial Board, 2014

Martin, L.M., Marples, B., Lynch, T.H., Hollywood, D., Marignol, L., Erratum to Exposure to low dose ionizing radiation: Molecular and clinical consequences [Cancer Lett. 338 (2) (2013) 209-218], 349, (1), 2014 Review Article, 2014

Flores AN, McDermott N, Meunier A, Marignol L, NUMB inhibition of NOTCH signalling as a therapeutic target in prostate cancer., Nature reviews. Urology, 11, (9), 2014, p499-507 Review Article, 2014

Azmi A, Dillon RA, Borghesi S, Dunne M, Power RE, Marignol L, O'Neill BD, Active surveillance for low-risk prostate cancer: diversity of practice across Europe., Irish journal of medical science, 2014 Journal Article, 2014

Kelada O, Marignol L, Erythropoietin-stimulating agents and clinical outcomes in metastatic breast cancer patients with chemotherapy-induced anemia: a closed debate?, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 35, (6), 2014, p5095-100 Review Article, 2014

McLaughlin, J., Marignol, L., Radiotherapy scheduling using prime numbers, Journal of Radiotherapy in Practice , 13, (3), 2014, p317-321 Journal Article, 2014 DOI

Mongan, A. M. and Lynam-Lennon, N. and Marignol, L. and Maher, S. and O'Farrell, N. J. and Pidgeon, G. and O'Sullivan, J. and Reynolds, J. V., Obesity fuels genomic instability and radioresistance in oesophageal cancer, 182, 2013, ppS38-S38 Poster, 2013

Røe K, Bratland A, Vlatkovic L, Ragnum HB, Saelen MG, Olsen DR, Marignol L, Ree AH, Hypoxic Tumor Kinase Signaling Mediated by STAT5A in Development of Castration-Resistant Prostate Cancer., PloS one, 8, (5), 2013, pe63723 Journal Article, 2013 TARA - Full Text DOI

Davies, A.M., Vajda, A., Ryan, S.L., Marignol, L., New approaches to cell based assays for high content screening and analysis, 18, (3), 2013, p23-28 Review Article, 2013

Vajda A, Marignol L, Barrett C, Madden SF, Lynch T, Hollywood D, Perry AS, Gene expression in prostate cancer: the importance of the endogenous control. , The Prostate, 2013 Journal Article, 2013

Marignol L, Rivera-Figueroa K, Lynch T, Hollywood D, Hypoxia, notch signalling, and prostate cancer., Nature reviews. Urology, 10, (7), 2013, p405-13 Review Article, 2013

Martin LM, Marples B, Davies AM, Atzberger A, Edwards C, Lynch TH, Hollywood D, Marignol L, DNA mismatch repair protein MSH2 dictates cellular survival in response to low dose radiation in endometrial carcinoma cells., Cancer letters, 2013 Journal Article, 2013

Bolton, E. M. and Moran, D. C. and Meunier, A. and O'Kelly, F. and Marignol, L. and Hollywood, D. and Lynch, T. H. and Perry, A. S., Real time expression analysis of a microRNA signature of prostate cancer in prostate cell lines and tissue specimens, 100, 2013, pp63-63 Poster, 2013

Martin LM, Marples B, Lynch TH, Hollywood D, Marignol L, Exposure to Low Dose Ionizing Radiation: Molecular and Clinical Consequences., Cancer letters, 2013 Review Article, 2013

Mongan, A. M. and Lynam-Lennon, N. and Marignol, L. and Maher, S. and Pidgeon, G. and O'Sullivan, J. N. and Reynolds, J. V., Obesity and radiosensitivity status influence genomic instability events: Anaphase bridge formation and spindle assembly checkpoint gene expression in oesophageal cancer, 100, 2013, pp48-48 Poster, 2013

McDermott N, Meunier A, Lynch T, Hollywood D, Marignol L, Isogenic radiation resistant cell lines: Development and Validation strategies., International journal of radiation biology, 2013 Review Article, 2013

Schoenherr D, Krueger SA, Martin L, Marignol L, Wilson GD, Marples B, Determining if low dose hyper-radiosensitivity (HRS) can be exploited to provide a therapeutic advantage: A cell line study in four glioblastoma multiforme (GBM) cell lines., International journal of radiation biology, 2013 Journal Article, 2013

Perry, A.S. and O'Hurley, G. and Raheem, O.A. and Brennan, K. and Wong, S. and O'Grady, A. and Kennedy, A.M. and Marignol, L. and Murphy, T.M. and Sullivan, L. and Barrett, C. and Loftus, B. and Thornhill, J. and Hewitt, S.M. and Lawler, M. and Kay, E. and Lynch, T. and Hollywood, D., Erratum: Gene expression and epigenetic discovery screen reveal methylation of SFRP2 in prostate cancer (International Journal of Cancer (2013) 132:8 (1771-80) DOI: 10.1002/ijc.27798)), International Journal of Cancer, 132, (11), 2013 Journal Article, 2013 DOI

Bolton, E. M. and Moran, D. and Meunier, A. and Vajda, A. and O'Kelly, F. and Thurman, J. and O'Connor, R. and Marignol, L. and Hollywood, D. and Lynch, T. H. and Perry, A. S., Epigenetic profiling in urine for the detection of aggressive prostate cancer, 100, 2013, pp63-63 Poster, 2013

Lynam-Lennon N, Reynolds JV, Marignol L, Sheils OM, Pidgeon GP, Maher SG, MicroRNA-31 modulates tumour sensitivity to radiation in oesophageal adenocarcinoma., Journal of molecular medicine (Berlin, Germany), 2012 Journal Article, 2012 DOI

Mongan, A. M. and Reynolds, J. and Lynam-Lennon, N. and Marignol, L. and Maher, S. and Pidgeon, G. and O'Sullivan, J., Obesity Status Influence Nuclear Instability Events: Anaphase Bridge Formation and Spindle Assembly Checkpoint Gene Expression in Oesophageal Cancer, 181, 2012, ppS152-S153 Poster, 2012

James C. Forde, Laure Marignol, Ophelia Blake, Ted McDermott, Ronald Grainger, Vivien E. Crowley, Thomas H. Lynch, Standardization of assay methods reduces variability of total PSA measurements: an Irish study, 2012 Poster, 2012 DOI

O'Kelly F, Marignol L, Meunier A, Lynch TH, Perry AS, Hollywood D, MicroRNAs as putative mediators of treatment response in prostate cancer., Nature reviews. Urology, 2012 Review Article, 2012 DOI

Bolton, E. and Moran, D. and Meunieur, A. and Marignol, L. and Hollywood, D. and Lynch, T. H. and Perry, A., Real Time Expression Analysis of a Microrna Signature of Prostate Cancer in Prostate Cell Lines and Tissue Specimens, 181, 2012, ppS169-S170 Poster, 2012

Azmi, Aini and Dillon, Ruth and Marignol, Laure and Borghesi, Simona and Dunne, Mary and Power, Richard and O'Neill, Brian, Active surveillance for low-risk prostate cancer: Practice across Europe, Journal of Clinical Oncology, 30, (5), 2012 Poster, 2012

Perry AS, O'Hurley G, Raheem OA, Brennan K, Wong S, O'Grady A, Kennedy AM, Marignol L, Murphy TM, Sullivan L, Barrett C, Loftus B, Thornhill J, Hewitt SM, Lawler M, Kay E, Lynch T, Hollywood D, Gene expression and epigenetic discovery screen reveal methylation of SFRP2 in prostate cancer., International journal of cancer. Journal international du cancer, 2012 Journal Article, 2012

Røe K, Mikalsen LT, van der Kogel AJ, Bussink J, Lyng H, Ree AH, Marignol L, Olsen DR, Vascular responses to radiotherapy and androgendeprivation therapy in experimental prostate cancer., Radiation oncology (London, England), 7, (1), 2012, p75 Journal Article, 2012

O'Kelly, F. and Perry, A. S. and Meunier, A. and Wong, S. and Hollywood, D. and Marignol, L. and Lynch, T. H., Over-expression of a novel microRNA, miR-24, affects prostate cancer cell growth and proliferation, and contributes to radio-senstivity of prostate cancer cells in vitro, 11, (1), 2012, ppE849-U790 Poster, 2012

Hennessey, D. and Coffey, M. and Lynch, T. and Lawler, M. and Hollywood, D. and Marignol, L., Adaptation to low oxygenation levels modify the radioresponse of prostate cancer cells in vitro, 98, (6), 2011, ppE8-E8 Poster, 2011

Lennon, N. Lynam and Reynolds, J. V. and Marignol, Laura and Sheils, O. M. and Pidgeon, G. P. and Maher, S. G., MiR-31 modulates tumour sensitivity to radiation in oesophageal cancer, 180, 2011, ppS276-S276 Poster, 2011

Foley R, Marignol L, Keane JP, Lynch TH, Hollywood D., Androgen hypersensitivity in prostate cancer: molecular perspectives on androgen deprivation therapy strategies, Prostate, 71, (5), 2011 Review Article, 2011 DOI

Mongan, A. M. and Reynolds, J. and Lynam-Lennon, N. and Marignol, L. and Maher, S. and Pidgeon, G. and O'Sullivan, J., Levels of obesity influences a nuclear instability event: Anaphase bridge formation in oesophageal cancer, 180, 2011, ppS262-S262 Poster, 2011

Forde, J. C. and Perry, A. and Hollywood, D. and Lawler, M. and Lynch, T. H. and Marignol, L., Downregulation of HIF-1 A and lowered TUBB3 expression levels leads to preferential sensitivity of hypoxic prostate cancer cells tol docetaxel, 98, (6), 2011, ppE8-E8 Poster, 2011

Vajda A, Marignol L, Foley R, Lynch TH, Lawler M, Hollywood D, Clinical potential of gene-directed enzyme prodrug therapy to improve radiation therapy in prostate cancer patients., Cancer treatment reviews, 37, (8), 2011, p643-54 Review Article, 2011

Hennessey D, Martin LM, Atzberger A, Lynch TH, Hollywood D, Marignol L, Exposure to hypoxia following irradiation increases radioresistance in prostate cancer cells., Urologic oncology, 1, 2011 Journal Article, 2011 DOI

Forde JC, Maginn EN, McNamara G, Martin LM, Campiani G, Williams DC, Zisterer D, McElligott AM, Lawler M, Lynch TH, Hollywood D, Marignol L, Microtubule-targeting-compound PBOX-15 radiosensitizes cancer cells in vitro., Cancer biology & therapy, 11, (4), 2011, p421-8 Journal Article, 2011

Forde, J. C. and Maginn, E. and McElligott, A. M. and Martin, L. M. and Williams, D. C. and Zisterer, D. and Lawler, M. and Hollywood, D. and Lynch, T. H. and Marignol, L., AN IN VITRO INVESTIGATION OF THE CYTOTOXIC AND RADIO-SENSITISING PROPERTIES OF A NOVEL MICROTUBULE TARGETING AGENT, PBOX-15, IN HYPOXIC PROSTATE CANCER CELL LINES, European Urology Supplements, EAU, 10, (2), 2011, pp292-292 Poster, 2011

Moran, D. and Marignol, L. and Fagan, A. and Hollywood, D. and Meaney, J. and Lynch, T., Functional endorectal MRI at 3 Tesla for the detection and staging of prostate cancer: Correlation with prostatectomy specimens, 180, 2011, ppS269-S270 Poster, 2011

Martin LM, Marples B, Coffey M, Lawler M, Lynch TH, Hollywood D, Marignol L, DNA mismatch repair and the DNA damage response to ionizing radiation: making sense of apparently conflicting data., Cancer treatment reviews, 36, (7), 2010, p518-27 Review Article, 2010 DOI

Forde JC, Perry AS, Brennan K, Martin LM, Lawler MP, Lynch TH, Hollywood D, Marignol L, Docetaxel maintains its cytotoxic activity under hypoxic conditions in prostate cancer cells., Urologic oncology, 1, 2010 Journal Article, 2010 DOI

Foley R, Marignol L, Keane JP, Lynch TH, Hollywood D, Comment on "Androgen-hypersensitive preclinical model of prostate cancer" by Kawata et al., The Prostate, 71, (6), 2010, p559 - 560 Review Article, 2010 DOI

Keane, J. P. and Foley, R. and Marignol, L. and Hollywood, D. and Lynch, T. H., THE EFFECT OF CALPAIN ACTIVATION IN THE 22Rv1 PROSTATE CANCER CELL LINE, 179, 2010, ppS350-S350 Published Abstract, 2010

Forde, J. C. and Hollywood, D. and Lawler, M. and Lynch, T. H. and Marignol, L. and Marignol, L., Investigation of the cytotoxic properties of a novel microtubule-targeting compound, PBOX-15, in hypoxic prostate cancer cell lines, Bju International, 106, (1), 2010, pp52-53 Poster, 2010

Hennessey, D. and Martin, L. and Hollywood, D. and Lynch, T. H. and Marignol, L., EXPOSURE TO REDUCED OXYGENATION FOLLOWING RADIATION EXPOSURE ENHANCES THE SURVIVAL OF PROSTATE CANCER CELLS IN VITRO: IMPLICATIONS FOR RADIATION THERAPY DELIVERY, Irish Medical Science Journal , IACR, 179, 2010, ppS351-S351 Published Abstract, 2010

Lynam-Lennon N, Reynolds JV, Pidgeon GP, Lysaght J, Marignol L, Maher SG, Alterations in DNA repair efficiency are involved in the radioresistance of esophageal adenocarcinoma., Radiation research, 174, (6), 2010, p703 - 711 Journal Article, 2010 DOI

Forde, J. C. and Blake, O. and Casey, R. G. and Marignol, L. and McDermott, T. E. and Grainger, R. and Crowley, V. E. and Lynch, T. H., THE INTER-HOSPITAL VARIABILITY OF 6 DIFFERENT PSA ASSAY KITS CURRENTLY IN USE THROUGHOUT IRELAND, Irish Journal of Medical Science, IACR, 179, 2010, ppS372-S372 Poster, 2010

Thomas, A. Z. and Foley, R. and Marignol, L. and Hollywood, D. and Lynch, T. and Lawlor, M., The effect of the HIF-1 alpha C1772T heterozygous genotype on prostate cancer risk and HIF-1 alpha expression in prostate tissue, 97, 2010, pp3-4 Poster, 2010

Forde, J. C. and Maginn, E. and McElligott, A. M. and Martin, L. M. and Williams, D. C. W. and Zisterer, D. and Hollywood, D. and Lawler, M. and Lynch, T. H. and Marignol, L., RADIOSENSITIZATION OF HYPOXIC PROSTATE CANCER CELL LINES USING A NOVEL MICROTUBULE TARGETING AGENT: PBOX-15, Irish Journal of Medical Science, IACR, 179, 2010, ppS372-S372 Poster, 2010

Martin L, Coffey M, Lawler M, Hollywood D, Marignol L, DNA mismatch repair and the transition to hormone independence in breast and prostate cancer., Cancer letters, 291, (2), 2010, p142-9 Review Article, 2010 DOI

Lynn Martin, Brian Marples, Mary Coffey, Mark Lawler, Donal Hollywood, Laure Marignol, Recognition of O6MeG lesions by MGMT and mismatch repair proficiency may be a prerequisite for low-dose radiation hypersensitivity., Radiation Research, 172, (4), 2009, p405 - 413 Journal Article, 2009

Marignol, L., Foley, R., Southgate, T.D., Coffey, M., Hollywood, D., Lawler, M., Hypoxia response element-driven cytosine deaminase/5-fluorocytosine gene therapy system: a highly effective approach to overcome the dynamics of tumour hypoxia and enhance the radiosensitivity of prostate cancer cells in vitro., The Journal of Gene Medicine , 11, (2), 2009, p169-179 Journal Article, 2009 DOI

Vajda, Alice and Marignol, Laure and Foley, Ruth and Hollywood, Donal and Lawler, Mark, Hypoxia, androgen and radiation-inducible suicide gene therapy for the treatment of prostate cancer, 20, (11), 2009, pp1519-1519 Poster, 2009

Foley R, Marignol L, Thomas AZ, Cullen IM, Perry AS, Tewari P, O'Grady A, Kay E, Dunne B, Loftus B, Watson WR, Fitzpatrick JM, Woodson K, Lehman T, Hollywood D, Lynch TH, Lawler M, The HIF-1alpha C1772T polymorphism may be associated with susceptibility to clinically localised prostate cancer but not with elevated expression of hypoxic biomarkers., Cancer biology & therapy, 8, (2), 2009, p118-24 Journal Article, 2009 TARA - Full Text

Raheem, O. A. and Powell, A. and Kennedy, A. M. and Murphy, T. and Foley, R. and Marignol, L., Investigation into methylation of the Secreted Frizzled Related Proteins (SFRP) family of Wnt antagonists in prostate cancer, 103, 2009, pp19-20 Poster, 2009

Marignol L, Coffey M, Lawler M, Hollywood D., Hypoxia in prostate cancer: a powerful shield against tumour destruction?, Cancer Treatment Reviews, 34, (4), 2008, p313-327 Review Article, 2008 DOI

Marignol L, Robson T, McCarthy HO, Worthington J, Murray MM, Hollywood D, Lawler M, Hirst DG., The tissue plasminogen activator gene promoter: a novel tool for radiogenic gene therapy of the prostate?, Journal of Gene Medicine, 10, (9), 2008, p1032-1038 Journal Article, 2008 DOI

D'Arcy, F. and Foley, R. and Perry, A. and Marignol, L. and Lawler, M. and Gaffney, E. and Watson, R. G. W. and Fitzpatrick, J. M. and Lynch, T. H., No evidence of XMRV in irish prostate cancer patients with the R462q mutation, 7, (3), 2008, pp271-271 Poster, 2008 DOI

Martin, L. and Marignol, L., Sequence effect on the survival of prostate cancer cells may potentiate daily radiation therapy delivery, 84, 2007, ppS281-S281 Poster, 2007

D'Arcy, F. and Foley, R. and Perry, A. and Marignol, L. and Gaffney, E. and Dunne, B. and Lawler, M. P. and Watson, R. W. G. and Fitzpatrick, J. M. and Lynch, T. H., RNASEL and its role in Irish prostate cancer patients, 100, 2007, pp12-13 Poster, 2007

Thomas, A. Z. and Marignol, L. and Foley, R. and Perry, A. and Tewari, P. and O'Grady, T. and Kay, E. and Dunne, B. and Loftus, B. and Hollywood, D. and Lynch, T. and Lawler, M., Enhanced expression of hypoxia markers in cell lines and in clinical specimens of malignant prostate tissue: A factor in disease progression?, 100, 2007, pp40-41 Poster, 2007

Thomas, A. Z. and Marignol, L. and Foley, R. and Perry, A. and Tewari, P. and O'Grady, T. and Kay, E. and Dunne, B. and Loftus, B. and Hollywood, D. and Lynch, T. and Lawler, M., Enhanced expression of hypoxia markers in cell lines and in clinical specimens of malignant prostate tissue: A factor in disease progression?, 100, 2007, pp40-41 Poster, 2007

Marignol L, Coffey M, Hollywood D, Lawler M., Radiation to Control Transgene Expression in Tumors., Cancer Biological Therapy, 6, (7), 2007, p1005 - 1012 Review Article, 2007 URL

Marignol, L. and Foley, R. and Southgate, T. D. and Coffey, M. and Hollywood, D. and Lawler, M., Hypoxia-inducible suicide gene therapy approach radiosensitises prostate cancer cells, 100, 2007, pp32-32 Published Abstract, 2007

Foley, R. and Marignol, L. and Lawler, M., Prodrug activation therapy kills prostate cancer cells in a three-dimensional culture model, 100, 2007, pp24-24 Poster, 2007

Traynor, S. and Gilham, C. and Foley, R. and Fairbairn, L. J. and Southgate, T. D. and Worthington, J. and Coffey, M. and Hollywood, D. and Lawler, M. and Marignol, L., Utilising a hypoxia-inducible suicide gene therapy strategy in combination with radiation to target prostate cancer cells, 81, 2006, ppS477-S477 Poster, 2006

Marignol L, Lawler M, Coffey M, Hollywood D., Achieving Hypoxia-Inducible Gene Expression in Tumors., Cancer Biological Therapy, 4, (4), 2005, p359-364. Review Article, 2005 URL

Research Expertise

Description

Radiobiology is a field of science that emerged from our ability to treat diseases with ionising radiation. I am intrigued by the complexity of the biological effects of radiation and feel compelled to pick at the puzzle. Cancer patients will never meet me, but I rejoice in the opportunity to help radiation Oncologists solve their challenges in ensuring that each patient can receive the best treatment for their disease. Radiobiology's pillars were defined by a few great and I feel privileged to have brought this field to Trinity and to both disseminate its legacy and contribute to its future in Ireland and internationally. I have extensively studied the impact of tumour microenvironmental factors on the biology of prostate tumours. My PhD work demonstrated that hypoxia could enable control therapeutic gene expression and has enabled others to purse this approach. My subsequent participation in the debate on the protective effect of hypoxia after radiation exposure, and its ability to affect the efficacy of commonly used chemotherapeutic agents shaped my transformation into an independent PI. My first grant selected for radioresistant prostate cancer cells, establishing a unique model to characterise the molecular mechanisms of the radiation response. I tested the prognostic potential of miRNAs, small, non-coding RNAs that negatively regulate gene expression, and identified novel miRNAs regulating radioresistance in prostate cancer cells. I proposed that the signalling pathways that regulate several cancer cells capabilities such as Notch and YB-1 as key to the survival of cancer cells to radiation, and identified deregulation of the Notch-3 receptor across cell line models of advancing disease stages and in patient specimens of high grade disease. My second grant examined the commercial potential of these findings for the development of a novel diagnostic test. Along the way, I have learnt that heterogeneity will prevail, and diversity in approaches is essential. I pushed the boundaries, investigating physical properties (functional imaging), learning the practical challenges of delivering radiotherapy, enabling my colleagues at the Discipline of Radiation Therapy to progress their research in the process. Together, we have demonstrated that molecular imaging techniques, such as magnetic resonance imaging (MRI), can advance our ability to assess prostate cancer; we have explored the impact of patient rotation on the treatment of lung cancer patient with radiotherapy. More recently I have questioned the potential impact of the differences between male and female biology. My next research objective is to enable my discoveries to inform both the prediction of clinical outcome to a radiotherapy treatment and the optimisation of a radiotherapy protocol to best treat tumours. To do so, next propose to devise a novel strategy for the selective generation of a large amount of DNA damage in single cancer cells. I have already, amongst others, demonstrated increased cell survival capacity in response to radiation exposure is associated with both reduced induction of DNA DSB and increased DNA repair capacity. While efforts to modify the DNA damage response are yielding encouraging results, this work will leverage my expertise and network, generate new opportunities while maintain the reputation of my unique, internationally recognised radiobiology lab and extended research group.

Projects

  • Title
    • Creating the next-generation Cancer cell DNA damaging agent
  • Summary
    • Our insufficient, biologically challenged or poorly targeted ability to generate fatal DNA damage in cancer cells is recognised as an underlying major limiting factor to therapeutic efficacy of current cancer treatments. While efforts to modify the DNA damage response are yielding encouraging results, few novel anti-cancer DNA damaging agents are emerging. This project aims to create the next generation cancer cell DNA damaging agent.
  • Date From
    • October 2020
  • Date To
    • Present
  • Title
    • Tumours have a sex: Impact on disease development and treatment response.
  • Summary
    • The issue of sex bias or sex dismorphism in science is rapidly gaining momentum. Sex is a variable that affects several biological functions including both the innate and adaptive immune systems, the mode of stress-induced cell death and pain responses. Sex-specific studies have highlighted that drugs may affect males and females differently. But the impact of sex on the radiation response remains largely unstudied. Our lab investigates the impact of sex as a biological variable in the response to anti-cancer treatment. This work would involve the generation of in vitro survival curves using both female and male cancer cell lines, the review of published and recorded clinical data, and a solid evaluation of the potential sex-specific differences in the behaviour of cancer cells.
  • Date From
    • October 2019
  • Date To
    • Ongoing
  • Title
    • Development of a Companion diAgnostic teSt for radiotheraPy prostAte canceR patients (CASPAR)
  • Summary
    • There is an unmet need to develop companion diagnostic tests that can guide patients and their clinicians through the treatment decision process. This project propose assesses a novel protein for its prognostic and therapeutic potential in high risk radiotherapy prostate cancer patients. The long-term focus of CASPAR is to develop a novel companion diagnostic test and therapeutic combination that can allow personalized prescription of radiotherapy for these patients.
  • Funding Agency
    • Science Foundation Ireland
  • Date From
    • 01/01/2017
  • Date To
    • 31/128/2017
  • Title
    • Prognosis potential of miRNAs in high risk radiotherapy prostate cancer patients
  • Summary
    • Failure to identify tumours with a radioresistant phenotype in the 1,000+ Irish prostate cancer patients/year receiving radiation therapy (RT) is associated with recurrence and decreased overall survival in approximatively 300-400 of these men, particularly those with localised Gleason 8-10 prostate carcinoma. This study aims to identify a miRNA panel that can be detected in diagnostic tissue biopsy specimen from high-risk patients, which will assist the identification of the 30-50% who are at greater risk of biochemical failure following RT.
  • Funding Agency
    • Irish Cancer Society
  • Date From
    • 01 December 2012
  • Date To
    • 01 December 2016
  • Title
    • Reduced oxygenation does not protect all prostate cancer cells from radiation: a new role for hypoxia in radiation therapy?
  • Summary
    • Oxygen is essential for optimal cytotoxicity of radiation therapy. In the absence of oxygen at the time of radiation exposure, cell survival is commonly expected to increase by up to three-fold. We proposed that the proportion of cells completely deprived of oxygen within tumours may not be sufficiently large to be clinically significant and hypothesised that the surrounding hypoxic cells in fact may govern tumour response to radiotherapy. To test this hypothesis, this study proposed to re-examine the radioresponse of hypoxic prostate cancer cells and determine the consequences of these potentially clinically relevant oxygen levels.

Keywords

Biological Markers; Biomedical Research Resources, Other; Cancer genetics and cell biology including metastasis; Cell Lines; Clinical Radiobiology; Data Management/Analysis; DNA; Drug Delivery Systems; Exercise; Gene Expression; Genetic Manipulation; Genomics; Inhibitors; Lung Cancer; Mathematical modelling; Medical Outcomes; Metabolism, Protein; Methods of Drug Delivery; Molecular Biology; Oncology; Precision Medicine; Prostate cancer; Proteins and Macromolecules; Radiomics; Radiotherapy; Radiotherapy, Biological response modifiers and chemoprevention; Sex differences in radiation biology; Stem Cell; Therapeutic and Clinical oncology; Tissue Culture; Transgene Expression; Urogenital System; Urology

Recognition

Representations

Environmental Protection Agency (EPA) Advisory Committee (Ireland) ( Minister Appointed Radiobiology advisor) July

Cancers (Special Issue Invited Guest Editor) July

European Society for Radiotherapy and Oncology, ESTRO 2021 Conference Scientific Advisory Group (Radiobiology Symposium development, Session chair, Abstract Reviewer) April

Basic Radiobiology Teaching Course, European Society for Radiotherapy and Oncology (Faculty member) September

University of Manchester, UK (PhD external Examiner) July

Royal College of Surgeons in Ireland, Faculty of Radiologists, FRCR Radiobiology Examination Preparation course (Radiation Oncology Registrars) (Radiobiology Course development, Instructor (Radiobiology); Tutor (Statistics)) June

University College Dublin, School of Medicine. Professional Certificate in Radiation Safety. (Curriculum developer, Instructor). June

Protocol for treatment interruption Compensation, Lung Radiation Therapy due to COVID-19 (Radiobiology Advisor) May

European Society for Radiotherapy and Oncology, ESTRO 2020 Conference Scientific Advisory Group (Radiobiology Symposium development, Session chair, Abstract Reviewer) December

Irish Radiation Research Society (Chair) February

European Society for Radiotherapy and Oncology, Radiobiology Committee (Invited Member)

St Luke's Radiation Oncology Network - Radiobiology Steering Committee (Invited member) May

Nature Scientific Reports (Editor) June

Journal Reviewer - Molecular Biology Reports Urology Advances in Radiation Oncology Experimental and Therapeutic Medicine Physics and Imaging in Radiation Oncology technical innovations and patient support in radiation oncology International Journal of Molecular Medicine Cancers June

The Wellcome - HRB Irish Clinical Academic Training Programme (Supervisor) June

Grant Reviewer - Medical Research Council (UK), COST Action (European Commission), EIT Health COVID Rapid response (European Commission), ERA PerMed (European Commission) June

Journal reviewer - Frontiers Oncology Clinical breast cancer Journal of Clinical Medicine Cells Molecular Oncology Oncology reports Oncology letters Oncotarget June

GANIL (Grand Accélérateur d'Ions Lourds) - Application Reviewing Committee member June

Queen's University Belfast, Northern Ireland (PhD external examiner) December

Irish Radiation Research Society (Deputy Chair) December

Irish Radiation Research Society (Secretary) December

Grant Reviewer - Leading Fellows Postdoc Programme (The Netherlands) March

University of Cape Town, South Africa (PhD external examiner) September

Irish Radiation Research Society (Treasurer) December

International Exchange, Global Health Disparities Research Training Program, Division of Public Health, Icahn School of Medicine at Mount Sinai, New York, USA. (Invited Mentor) July

University of New South Wales, Australia (PhD external examiner) November

Awards and Honours

Election to Fellowship, Trinity College Dublin 10/04/2017

Faculty of Health Sciences, Dean's Research Award 2020

Cancer Immunology Stimulus Award 2018

GANIL (Grand Accélérateur d'Ions Lourds) Beam Access Award 2018

Faculty of Health Sciences, Dean's Teaching Award 2015

Science Foundation Ireland, TIDA 2017

Early Career Investigator Award, Radiation Research Society (USA) October 2017

Irish Cancer Society, Prostate Cancer Project Grant 01/12/2012

Travel Award, Radiation Research Society, USA 2010

6th St Lukes Young Investigator Award 2009

Early investigator award, Association for Radiation Research (UK) 2007

Memberships

Irish Radiation Research Society 2013 – Present

European Society for Radiotherapy and Oncology (ESTRO) 2009 – Present

Radiation Research Society (USA) 2007 – Present

Irish Association for Cancer Research 2003 – Present